Agios shapes up to be among the strongest biotechs to go public last year

With a recent full-length feature article in The New Yorker magazine and the enthusiastic support of Jim Cramer of CNBC, Cambridge-based Agios Pharmaceuticals is shaping up to be one of the most successful biotechs of the local IPO class of 2013...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.